NQF 0022: Use of High-Risk Medications in the Elderly

Measure: Record the percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported:
a. Percentage of patients who were ordered at least one high-risk medication.
b. Percentage of patients who were ordered at least two different high-risk
medications.
Numerator 1: Patients who meet the denominator and have an order for at least one high-risk medication during the measurement period.
Numerator 2: Patients who meet the denominator and have an order for at least two different high-risk medications during the measurement period.
Denominator: Patients 66 years and older who had a visit with the EP during the measurement period.
Exclusion:  None
NQS Domain: Patient Safety

In ChartMaker Clinical:

In order to qualify for this measure, the provider must have seen the patient at least two times during the reporting period and have the appropriate information documented in the chart:

Required Data Elements for the Denominator*:

• Office Encounter Code or Face-to-Face Interaction (SNOMED) Code during the measurement period
Valid Office Encounter Codes: 
CPT: 
CodeDescription
99201Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.
99202Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent face-to-face with the patient and/or family.
99203Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.
99204Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
99205Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.
99212Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.
99213Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99214Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99215Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.
99341Home visit for the evaluation and management of a new patient, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low severity. Typically, 20 minutes are spent face-to-face with the patient and/or family.
99342Home visit for the evaluation and management of a new patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.
99343Home visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
99344Home visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.
99345Home visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant new problem requiring immediate physician attention. Typically, 75 minutes are spent face-to-face with the patient and/or family.
99347Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99348Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99349Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.
99350Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive interval history; A comprehensive examination; Medical decision making of moderate to high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. The patient may be unstable or may have developed a significant new problem requiring immediate physician attention. Typically, 60 minutes are spent face-to-face with the patient and/or family.
99385Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years
99386Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years
99387Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 65 years and older
99395Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years
99396Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years
99397Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 65 years and older
G0438Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit
G0439Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit
Valid Face-to-Face Encounter Codes:
SNOMED: 
CodeDescription
12843005Subsequent hospital visit by physician (procedure)
18170008Subsequent nursing facility visit (procedure)
19681004Nursing evaluation of patient and report (procedure)
87790002Follow-up inpatient consultation visit (procedure)
90526000Initial evaluation and management of healthy individual (procedure)
185349003Encounter for "check-up" (procedure)
185463005Visit out of hours (procedure)
185465003Weekend visit (procedure)
207195004History and physical examination with evaluation and management of nursing facility patient (procedure)
270427003Patient-initiated encounter (procedure)
270430005Provider-initiated encounter (procedure)
308335008Patient encounter procedure (procedure)
390906007Follow-up encounter (procedure)
406547006Urgent follow-up (procedure)
439708006Home visit (procedure)

 

Required Data Elements for Numerator 1*:

• High-Risk Medications for the Elderly or High-Risk Medications with Days Supply of greater than 90 during the measurement period
  • {12 (Acetaminophen 325 MG / Chlorpheniramine Maleate 2 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet) / 12 (Acetaminophen 325 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet) } Pack
  • {14 (Estrogens, Conjugated (USP) 0.625 MG / medroxyprogesterone acetate 5 MG Oral Tablet) / 14 (Estrogens, Conjugated (USP) 0.625 MG Oral Tablet) } Pack
  • {28 (Estrogens, Conjugated (USP) 0.3 MG / medroxyprogesterone acetate 1.5 MG Oral Tablet) } Pack
  • {28 (Estrogens, Conjugated (USP) 0.45 MG / medroxyprogesterone acetate 1.5 MG Oral Tablet) } Pack
  • {28 (Estrogens, Conjugated (USP) 0.625 MG / medroxyprogesterone acetate 2.5 MG Oral Tablet) } Pack
  • {28 (Estrogens, Conjugated (USP) 0.625 MG / medroxyprogesterone acetate 5 MG Oral Tablet) } Pack
  • 1 ML Diphenhydramine Hydrochloride 50 MG/ML Prefilled Syringe
  • 12 HR Atropine Sulfate 0.04 MG / Chlorpheniramine Maleate 8 MG / Hyoscyamine Sulfate 0.19 MG / Pseudoephedrine Hydrochloride 90 MG / Scopolamine Hydrobromide 0.01 MG Extended Release Oral Tablet
  • Acetaminophen 163 MG / Chlorpheniramine Maleate 2 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet
  • Acetaminophen 2.71 MG/ML / Diphenhydramine Hydrochloride 0.104 MG/ML / Phenylephrine Hydrochloride 0.0417 MG/ML Oral Solution
  • Acetaminophen 21.7 MG/ML / Chlorpheniramine Maleate 0.133 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML Oral Solution
  • Acetaminophen 21.7 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML / doxylamine succinate 0.417 MG/ML Oral Solution
  • Acetaminophen 32 MG/ML / Chlorpheniramine Maleate 0.2 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML Oral Solution
  • Acetaminophen 32 MG/ML / Diphenhydramine Hydrochloride 1.25 MG/ML / Phenylephrine Hydrochloride 0.5 MG/ML Oral Solution
  • Acetaminophen 325 MG / Chlorpheniramine Maleate 2 MG / Dextromethorphan Hydrobromide 10 MG / Phenylephrine Hydrochloride 5 MG Oral Capsule
  • Acetaminophen 325 MG / Chlorpheniramine Maleate 2 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet
  • Acetaminophen 325 MG / Diphenhydramine Hydrochloride 12.5 MG Oral Tablet
  • Acetaminophen 325 MG / Diphenhydramine Hydrochloride 25 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet
  • Acetaminophen 325 MG / doxylamine succinate 6.25 MG / Phenylephrine Hydrochloride 5 MG Oral Capsule
  • Acetaminophen 33.3 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML / doxylamine succinate 0.417 MG/ML Oral Solution
  • Acetaminophen 500 MG / Chlorpheniramine Maleate 2 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet
  • Acetaminophen 500 MG / Diphenhydramine Hydrochloride 12.5 MG Oral Tablet
  • Brompheniramine Tannate 0.8 MG/ML / Phenylephrine Tannate 1 MG/ML Oral Suspension
  • Brompheniramine Tannate 1 MG/ML / Phenylephrine Tannate 1 MG/ML Oral Suspension
  • butabarbital 15 MG / Hyoscyamine hydrobromide 0.3 MG / Phenazopyridine hydrochloride 150 MG Oral Tablet
  • CARBETAPENTANE CITRATE 4 MG/ML / Carbinoxamine maleate 1 MG/ML / Phenylephrine Hydrochloride 2 MG/ML Oral Solution
  • Carbinoxamine maleate 0.334 MG/ML Oral Solution
  • Carbinoxamine maleate 0.8 MG/ML / Dextromethorphan Hydrobromide 3 MG/ML / Pseudoephedrine Hydrochloride 12 MG/ML Oral Solution
  • Carbinoxamine maleate 0.8 MG/ML Oral Solution
  • Carbinoxamine maleate 1 MG/ML / Dextromethorphan Hydrobromide 2 MG/ML / Phenylephrine Hydrochloride 2 MG/ML Oral Solution
  • Carbinoxamine maleate 1 MG/ML / Phenylephrine Hydrochloride 2 MG/ML Oral Solution
  • Carbinoxamine maleate 1.5 MG/ML / Phenylephrine Hydrochloride 1.5 MG/ML Oral Solution
  • Carbinoxamine maleate 2 MG/ML / Dextromethorphan Hydrobromide 3 MG/ML / Phenylephrine Hydrochloride 2 MG/ML Oral Solution
  • Carbinoxamine maleate 2 MG/ML / Phenylephrine Hydrochloride 2 MG/ML Oral Solution
  • Carbinoxamine maleate 4 MG Oral Tablet
  • Carbinoxamine maleate 8 MG / Phenylephrine Hydrochloride 40 MG Extended Release Oral Tablet
  • Carbinoxamine Tannate 0.4 MG/ML / PSEUDOEPHEDRINE TANNATE 3 MG/ML Oral Suspension
  • Carbinoxamine Tannate 0.4 MG/ML Oral Suspension
  • Carbinoxamine Tannate 0.64 MG/ML Oral Suspension
  • Carbinoxamine Tannate 0.72 MG/ML / PSEUDOEPHEDRINE TANNATE 9.04 MG/ML Extended Release Suspension
  • Carbinoxamine Tannate 0.72 MG/ML Extended Release Suspension
  • Chlorpheniramine Maleate 0.4 MG/ML / Codeine Phosphate 2 MG/ML / Phenylephrine Hydrochloride 1 MG/ML Oral Solution
  • Chlorpheniramine Maleate 0.4 MG/ML / Pseudoephedrine Hydrochloride 6 MG/ML Oral Solution
  • Chlorpheniramine Maleate 2 MG / Dextromethorphan Hydrobromide 10 MG / Pseudoephedrine Hydrochloride 30 MG Chewable Tablet
  • Chlorpheniramine Maleate 2 MG / Pseudoephedrine Hydrochloride 30 MG Chewable Tablet
  • Chlorpheniramine Maleate 3 MG / Phenylephrine Hydrochloride 10 MG Oral Tablet
  • Chlorpheniramine Maleate 4 MG / Phenylephrine Hydrochloride 10 MG / Pyrilamine Maleate 25 MG Oral Tablet
  • Diphenhydramine Hydrochloride 12.5 MG Chewable Tablet
  • Diphenhydramine Hydrochloride 12.5 MG Oral Strip
  • Diphenhydramine Hydrochloride 2.5 MG/ML Oral Solution
  • Diphenhydramine Hydrochloride 25 MG / Phenylephrine Hydrochloride 10 MG Oral Tablet
  • Diphenhydramine Hydrochloride 25 MG Oral Capsule
  • Diphenhydramine Hydrochloride 25 MG Oral Strip
  • Diphenhydramine Hydrochloride 25 MG Oral Tablet
  • Diphenhydramine Hydrochloride 50 MG Oral Capsule
  • Estrogens, Conjugated (USP) 0.3 MG / medroxyprogesterone acetate 1.5 MG Oral Tablet
  • Estrogens, Conjugated (USP) 0.45 MG / medroxyprogesterone acetate 1.5 MG Oral Tablet
  • Estrogens, Conjugated (USP) 0.625 MG / medroxyprogesterone acetate 2.5 MG Oral Tablet
  • Estrogens, Conjugated (USP) 0.625 MG / medroxyprogesterone acetate 5 MG Oral Tablet
  • thyroid (USP) 97.5 MG Oral Tablet
  • Eszopiclone 1 MG Oral TabletValid High-Risk Medications with Days Supply Criteria:
    • Eszopiclone 2 MG Oral Tablet
    • Eszopiclone 3 MG Oral Tablet
    • Nitrofurantoin 100 MG Oral Capsule
    • Nitrofurantoin 25 MG Oral Capsule
    • Nitrofurantoin 5 MG/ML Oral Suspension
    • Nitrofurantoin 50 MG Oral Capsule
    • zaleplon 10 MG Oral Capsule
    • zaleplon 5 MG Oral Capsule
    • Zolpidem tartrate 1.75 MG Sublingual Tablet
    • Zolpidem tartrate 10 MG Oral Tablet
    • Zolpidem tartrate 10 MG Sublingual Tablet
    • Zolpidem tartrate 12.5 MG Extended Release Oral Tablet
    • Zolpidem tartrate 3.5 MG Sublingual Tablet
    • Zolpidem tartrate 5 MG Oral Tablet
    • Zolpidem tartrate 5 MG Sublingual Tablet
    • Zolpidem tartrate 5 MG/ACTUAT Oral Spray
    • Zolpidem tartrate 6.25 MG Extended Release Oral Tablet

     

    Required Data Elements for Numerator 2*:

    • 2 or more High-Risk Medications for the Elderly or High-Risk Medications with Days Supply of greater than 90 during the measurement period
    • {12 (Acetaminophen 325 MG / Chlorpheniramine Maleate 2 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet) / 12 (Acetaminophen 325 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet) } Pack
    • {14 (Estrogens, Conjugated (USP) 0.625 MG / medroxyprogesterone acetate 5 MG Oral Tablet) / 14 (Estrogens, Conjugated (USP) 0.625 MG Oral Tablet) } Pack
    • {28 (Estrogens, Conjugated (USP) 0.3 MG / medroxyprogesterone acetate 1.5 MG Oral Tablet) } Pack
    • {28 (Estrogens, Conjugated (USP) 0.45 MG / medroxyprogesterone acetate 1.5 MG Oral Tablet) } Pack
    • {28 (Estrogens, Conjugated (USP) 0.625 MG / medroxyprogesterone acetate 2.5 MG Oral Tablet) } Pack
    • {28 (Estrogens, Conjugated (USP) 0.625 MG / medroxyprogesterone acetate 5 MG Oral Tablet) } Pack
    • 1 ML Diphenhydramine Hydrochloride 50 MG/ML Prefilled Syringe
    • 12 HR Atropine Sulfate 0.04 MG / Chlorpheniramine Maleate 8 MG / Hyoscyamine Sulfate 0.19 MG / Pseudoephedrine Hydrochloride 90 MG / Scopolamine Hydrobromide 0.01 MG Extended Release Oral Tablet
    • Acetaminophen 163 MG / Chlorpheniramine Maleate 2 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet
    • Acetaminophen 2.71 MG/ML / Diphenhydramine Hydrochloride 0.104 MG/ML / Phenylephrine Hydrochloride 0.0417 MG/ML Oral Solution
    • Acetaminophen 21.7 MG/ML / Chlorpheniramine Maleate 0.133 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML Oral Solution
    • Acetaminophen 21.7 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML / doxylamine succinate 0.417 MG/ML Oral Solution
    • Acetaminophen 32 MG/ML / Chlorpheniramine Maleate 0.2 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML Oral Solution
    • Acetaminophen 32 MG/ML / Diphenhydramine Hydrochloride 1.25 MG/ML / Phenylephrine Hydrochloride 0.5 MG/ML Oral Solution
    • Acetaminophen 325 MG / Chlorpheniramine Maleate 2 MG / Dextromethorphan Hydrobromide 10 MG / Phenylephrine Hydrochloride 5 MG Oral Capsule
    • Acetaminophen 325 MG / Chlorpheniramine Maleate 2 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet
    • Acetaminophen 325 MG / Diphenhydramine Hydrochloride 12.5 MG Oral Tablet
    • Acetaminophen 325 MG / Diphenhydramine Hydrochloride 25 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet
    • Acetaminophen 325 MG / doxylamine succinate 6.25 MG / Phenylephrine Hydrochloride 5 MG Oral Capsule
    • Acetaminophen 33.3 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML / doxylamine succinate 0.417 MG/ML Oral Solution
    • Acetaminophen 500 MG / Chlorpheniramine Maleate 2 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet
    • Acetaminophen 500 MG / Diphenhydramine Hydrochloride 12.5 MG Oral Tablet
    • Brompheniramine Tannate 0.8 MG/ML / Phenylephrine Tannate 1 MG/ML Oral Suspension
    • Brompheniramine Tannate 1 MG/ML / Phenylephrine Tannate 1 MG/ML Oral Suspension
    • butabarbital 15 MG / Hyoscyamine hydrobromide 0.3 MG / Phenazopyridine hydrochloride 150 MG Oral Tablet
    • CARBETAPENTANE CITRATE 4 MG/ML / Carbinoxamine maleate 1 MG/ML / Phenylephrine Hydrochloride 2 MG/ML Oral Solution
    • Carbinoxamine maleate 0.334 MG/ML Oral Solution
    • Carbinoxamine maleate 0.8 MG/ML / Dextromethorphan Hydrobromide 3 MG/ML / Pseudoephedrine Hydrochloride 12 MG/ML Oral Solution
    • Carbinoxamine maleate 0.8 MG/ML Oral Solution
    • Carbinoxamine maleate 1 MG/ML / Dextromethorphan Hydrobromide 2 MG/ML / Phenylephrine Hydrochloride 2 MG/ML Oral Solution
    • Carbinoxamine maleate 1 MG/ML / Phenylephrine Hydrochloride 2 MG/ML Oral Solution
    • Carbinoxamine maleate 1.5 MG/ML / Phenylephrine Hydrochloride 1.5 MG/ML Oral Solution
    • Carbinoxamine maleate 2 MG/ML / Dextromethorphan Hydrobromide 3 MG/ML / Phenylephrine Hydrochloride 2 MG/ML Oral Solution
    • Carbinoxamine maleate 2 MG/ML / Phenylephrine Hydrochloride 2 MG/ML Oral Solution
    • Carbinoxamine maleate 4 MG Oral Tablet
    • Carbinoxamine maleate 8 MG / Phenylephrine Hydrochloride 40 MG Extended Release Oral Tablet
    • Carbinoxamine Tannate 0.4 MG/ML / PSEUDOEPHEDRINE TANNATE 3 MG/ML Oral Suspension
    • Carbinoxamine Tannate 0.4 MG/ML Oral Suspension
    • Carbinoxamine Tannate 0.64 MG/ML Oral Suspension
    • Carbinoxamine Tannate 0.72 MG/ML / PSEUDOEPHEDRINE TANNATE 9.04 MG/ML Extended Release Suspension
    • Carbinoxamine Tannate 0.72 MG/ML Extended Release Suspension
    • Chlorpheniramine Maleate 0.4 MG/ML / Codeine Phosphate 2 MG/ML / Phenylephrine Hydrochloride 1 MG/ML Oral Solution
    • Chlorpheniramine Maleate 0.4 MG/ML / Pseudoephedrine Hydrochloride 6 MG/ML Oral Solution
    • Chlorpheniramine Maleate 2 MG / Dextromethorphan Hydrobromide 10 MG / Pseudoephedrine Hydrochloride 30 MG Chewable Tablet
    • Chlorpheniramine Maleate 2 MG / Pseudoephedrine Hydrochloride 30 MG Chewable Tablet
    • Chlorpheniramine Maleate 3 MG / Phenylephrine Hydrochloride 10 MG Oral Tablet
    • Chlorpheniramine Maleate 4 MG / Phenylephrine Hydrochloride 10 MG / Pyrilamine Maleate 25 MG Oral Tablet
    • Diphenhydramine Hydrochloride 12.5 MG Chewable Tablet
    • Diphenhydramine Hydrochloride 12.5 MG Oral Strip
    • Diphenhydramine Hydrochloride 2.5 MG/ML Oral Solution
    • Diphenhydramine Hydrochloride 25 MG / Phenylephrine Hydrochloride 10 MG Oral Tablet
    • Diphenhydramine Hydrochloride 25 MG Oral Capsule
    • Diphenhydramine Hydrochloride 25 MG Oral Strip
    • Diphenhydramine Hydrochloride 25 MG Oral Tablet
    • Diphenhydramine Hydrochloride 50 MG Oral Capsule
    • Estrogens, Conjugated (USP) 0.3 MG / medroxyprogesterone acetate 1.5 MG Oral Tablet
    • Estrogens, Conjugated (USP) 0.45 MG / medroxyprogesterone acetate 1.5 MG Oral Tablet
    • Estrogens, Conjugated (USP) 0.625 MG / medroxyprogesterone acetate 2.5 MG Oral Tablet
    • Estrogens, Conjugated (USP) 0.625 MG / medroxyprogesterone acetate 5 MG Oral Tablet
    • thyroid (USP) 97.5 MG Oral Tablet
     
    Eszopiclone 1 MG Oral TabletValid High-Risk Medications with Days Supply Criteria:
    • Eszopiclone 2 MG Oral Tablet
    • Eszopiclone 3 MG Oral Tablet
    • Nitrofurantoin 100 MG Oral Capsule
    • Nitrofurantoin 25 MG Oral Capsule
    • Nitrofurantoin 5 MG/ML Oral Suspension
    • Nitrofurantoin 50 MG Oral Capsule
    • zaleplon 10 MG Oral Capsule
    • zaleplon 5 MG Oral Capsule
    • Zolpidem tartrate 1.75 MG Sublingual Tablet
    • Zolpidem tartrate 10 MG Oral Tablet
    • Zolpidem tartrate 10 MG Sublingual Tablet
    • Zolpidem tartrate 12.5 MG Extended Release Oral Tablet
    • Zolpidem tartrate 3.5 MG Sublingual Tablet
    • Zolpidem tartrate 5 MG Oral Tablet
    • Zolpidem tartrate 5 MG Sublingual Tablet
    • Zolpidem tartrate 5 MG/ACTUAT Oral Spray
    • Zolpidem tartrate 6.25 MG Extended Release Oral Tablet

    *ADDITIONAL INFORMATION:

    •  The patient must be 66 years of age or older prior to the start of the measurement period.

    • The intent of Numerator 1 of the measure is to assess if the patient has been prescribed at least one high-risk medication.

    • The intent of Numerator 2 of the measure is to assess if the patient has been prescribed at least two different high-risk medications.

    •  The days supply of greater than 90 is determined using CUMULATIVE MEDICATION DURATION.  This is an individual’s total number of medication days over a specific period (the measurement period); the period counts multiple prescriptions with gaps in between, but does not count the gaps during which a medication was not dispensed.
    To determine the cumulative medication duration, determine first the number of the Medication Days for each prescription in the period: the number of doses divided by the dose frequency per day. Then add the Medication Days for each prescription without counting any days between the prescriptions.

    •  The only data used to determine the denominator is data from the ChartMaker Clinical Module. If a patient encounter was not entered into the ChartMaker Clinical Module, that encounter is not included in the denominator for the statistical calculations on the Meaningful Use Dashboard. Please add these additional patients to the denominator and recalculate the percentage for Attestation purposes.

     

    Check the types of e-mail notifications you want sent to this address: